VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 10, 2026

Stock Comparison

Intertek Group plc vs Vertex Pharmaceuticals Incorporated

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Intertek Group plc

ITRK · London Stock Exchange

Market cap (USD)$7.1B
Gross margin (TTM)16.9%
Operating margin (TTM)16.9%
Net margin (TTM)9.9%
SectorIndustrials
IndustrySpecialty Business Services
CountryGB
Data as of2025-12-28
Moat score
64/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Intertek Group plc's moat claims, evidence, and risks.

View ITRK analysis

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Market cap (USD)$119B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
IndustryBiotechnology
CountryUS
Data as of2026-01-08
Moat score
99/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Vertex Pharmaceuticals Incorporated's moat claims, evidence, and risks.

View VRTX analysis

Comparison highlights

  • Moat score gap: Vertex Pharmaceuticals Incorporated leads (99 / 100 vs 64 / 100 for Intertek Group plc).
  • Segment focus: Intertek Group plc has 5 segments (28.3% in Consumer Products); Vertex Pharmaceuticals Incorporated has 3 segments (99.9% in Cystic Fibrosis CFTR Modulators).
  • Primary market structure: Oligopoly vs Quasi-Monopoly. Pricing power: Strong vs Strong.
  • Moat breadth: Intertek Group plc has 6 moat types across 3 domains; Vertex Pharmaceuticals Incorporated has 7 across 4.

Primary market context

Intertek Group plc

Consumer Products

Market

Consumer products testing, inspection and certification (TIC/ATIC) services

Geography

Global

Customer

Brands, retailers, manufacturers

Role

Third-party conformity assessment and supply chain QA

Revenue share

28.3%

Vertex Pharmaceuticals Incorporated

Cystic Fibrosis CFTR Modulators

Market

CFTR modulator therapies for cystic fibrosis

Geography

U.S., Europe, Australia, Canada

Customer

Patients (via specialty pharmacies/payers); CF care centers

Role

Drug developer/manufacturer

Revenue share

99.9%

Side-by-side metrics

Intertek Group plc
Vertex Pharmaceuticals Incorporated
Ticker / Exchange
ITRK - London Stock Exchange
VRTX - NASDAQ
Market cap (USD)
$7.1B
$119B
Gross margin (TTM)
16.9%
n/a
Operating margin (TTM)
16.9%
n/a
Net margin (TTM)
9.9%
n/a
Sector
Industrials
Healthcare
Industry
Specialty Business Services
Biotechnology
HQ country
GB
US
Primary segment
Consumer Products
Cystic Fibrosis CFTR Modulators
Market structure
Oligopoly
Quasi-Monopoly
Market share
n/a
70%-78% (reported)
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
64 / 100
99 / 100
Moat domains
Supply, Demand, Legal
Legal, Demand, Financial, Supply
Last update
2025-12-28
2026-01-08

Moat coverage

Shared moat types

Service Field Network

Intertek Group plc strengths

Data Workflow LockinBrand TrustCompliance AdvantageSuite BundlingDesign In Qualification

Vertex Pharmaceuticals Incorporated strengths

IP Choke PointGovernment Contracting RelationshipsSwitching Costs GeneralBenchmark Pricing PowerRegulated Standards PipeCapacity Moat

Segment mix

Intertek Group plc segments

Full profile >

Consumer Products

Oligopoly

28.3%

Corporate Assurance

Competitive

14.6%

Health and Safety

Competitive

9.9%

Industry and Infrastructure

Competitive

24.9%

World of Energy

Oligopoly

22.3%

Vertex Pharmaceuticals Incorporated segments

Full profile >

Cystic Fibrosis CFTR Modulators

Quasi-Monopoly

99.9%

Hemoglobinopathies Gene Therapy (CASGEVY)

Oligopoly

0.1%

Acute Pain (JOURNAVX)

Competitive

n/a

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.